ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB<sub>1</sub> receptor with a binding affinity of K<sub>i</sub> = 0.09 nM and an EC<sub>50</sub> of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of K<sub>i</sub>, it is not the most potent compound at producing a CB<sub>1</sub> mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC<sub>50</sub> values.
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.